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Abstract Many countries now have guidelines on the
clinical management of acute otitis media. In almost all,
the public health goal of containing acquired resistance in
bacteria through reduced antibiotic prescribing is the main
aim and basis for recommendations. Despite some partial
short-term successes, clinical activity databases and opinion
surveys suggest that such restrictive guidelines are not
followed closely, so this aim is not achieved. Radical new
solutions are needed to tackle irrationalities in healthcare
systems which set the short-term physician–patient relation-
ship against long-term public health. Resolving this opposi-
tion will require comprehensive policy appraisal and co-
ordinated actions at many levels, not just dissemination of
evidence and promotion of guidelines. The inappropriate
clinical rationales that underpin non-compliance with guide-
lines can be questioned by evidence, but also need specific
developments promoting alternative solutions, within a
framework of whole-system thinking. Promising develop-
ments would be (a) physician training modules on age-
appropriate analgesia and on detection plus referral of rare
complications like mastoiditis, and (b) vaccination against
the most common and serious bacterial pathogens.
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AOM Acute otitis media
OME Otitis media with effusions
Introduction: the challenge of marginal efficacy
Otitis media (OM) is a very common childhood infection of
the middle ear facilitated by seasonal respiratory viruses.
Incidence peaks between 6 months and 2 years, by which
age over 90% of children have had at least one episode of
acute OM (AOM) [72]. A proportion will develop OM with
effusion (OME), with consequences which reach well into
mid-childhood [53]. AOM is generally self-limiting, but its
recurrence and frequency entail high direct healthcare costs
[50] and indirect costs for parents [42], as well as burden on
family quality of life [14]. Despite a superficial familiarity,
OM still poses many challenges of definition, assessment,
and indications for treatment.
Even with insensitive traditional culture methods, about
70% of middle ears in AOM yield bacterial isolates [96], so
most of properly diagnosed (and severe) AOM is seen as
bacterial [55, 67]. Over-inclusive diagnosis by non-
specialists may result in antibiotic prescribing for condi-
tions that are not actually bacterial. Routine microbiological
assessment (by paracentesis) is impractical and mostly
thought unethical. Hence, antibiotics give frustratingly
small benefits [39, 56, 61] compared to temporizing care
with analgesics [88]. Even with appropriate diagnosis, the
overall clinical effectiveness of antibiotics remains low for
reasons which are now well understood, including: poor
penetration into the middle ear mucosa [19]; inaccessibility
of bacteria in the form of biofilm [48]; little symptomatic
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course in most patients if untreated [84]; and poor
adherence to treatment regimens [15]. The treatment
dilemma is intensified by the emergence of strains resistant
to antibiotics [9], which has become the main stimulus to
guidelines, discussed further below.
Recent reductions in consultations for AOM [78, 102,
103] are too large and pervasive to be due to one single
factor. Guidelines must have contributed, in part, to “de-
medicalization” of AOM. The exact contribution of
changes in clinical practice and health systems are hard
to distinguish so guidelines are best seen as flags of a
trend rather than the root cause. Trials suggest that the
contribution of pneumococcal vaccination to all-cause
reduction in OM is no more than modest [18, 28, 80]
and observational studies on all-cause OM consultations
post-vaccine are poorly controlled for background trends
like the de-medicalization from guidelines [93]. Reduction
in the more serious (and more clearly diagnosable)
pneumococcal OM is not in question.
Antibiotic prescription rates per consultation for AOM
remain high in most countries (approximately 80% of all
consultations) [102], and especially in children <2 years
[72]. This may be due to a fixed notion of an appropriate
prescription rate. Parents’ criteria for consultation may have
become both higher and narrower (family-level triage)
making more consultations justify a prescription. A further
possibility is time pressure as an opportunity cost: the
relatively modest cost to the healthcare system of many
antibiotics, against the personnel cost for assessment and
explanation required in rational prescribing, create an
incentive to over-prescribe. The multiple possible explan-
ations for stable prescription rates per consultation amid
reduced consultations add to the present requirement for a
whole-system examination of the main policy dilemmas
around antibiotics in OM, separate from mere promotion of
guidelines.
Antibiotic resistance—the driver for change
At recent rates of spread of resistance, the low rate of
discovery of new antimicrobials will soon compromise
mankind’s ability to fight serious infections, including
prophylaxis to control infection during surgery [58, 101].
Bacteriological time series data reflect the selection
pressures for the development of antibiotic resistance. The
European Surveillance of Antimicrobial Consumption
findings from 2001 [40], replicated in 2004 [97], estab-
lished firmly the link between antibiotic consumption and
resistance. Countries can be at differing phases of a cycle in
consumption and bacterial response [29]: rates of resistance
have been rising in Ireland and Finland, but remain low in
Germany and The Netherlands. Encouragingly, reducing
prescription rates in France, Belgium, and Spain, (former)
high-consumption countries, seem to be giving lower levels
of resistance (Fig. 1)[ 29].
OM is a major public health issue because it is a prime
target for rational prescribing [24]. It dominates antibiotic
consumption, even in low-consumption countries with low
OM concern [87]. Secondly, the high incidence and low
antibiotic efficacy in OM favor mutation and survival of
resistant strains. In infants <2 year, 90% of antibiotic
prescriptions are for OM [72], and the number and
proximity of contacts in child day care create a particularly
effective “forcing ground” for the spread of resistance [43],
reflected in locally differing prescription rates for OM [6].
Thus OM particularly justifies guidelines and related
developments to restrict prescribing.
Guidelines: formulation and presentation
Guidelines on management of AOM (and of upper
respiratory tract infections more generally) draw on shared
evidence and clinical insights from a coherent literature.
They recommend “watchful waiting” in children >2 years
with uncomplicated AOM, and limit immediate prescription
to those most likely to benefit, i.e., the very young and
those with a firm diagnosis (Table 1). All guidelines stratify
eligible patients by age, duration, and severity, although the
recommended cut-offs differ between countries. These
details are probably less important than whether a guideline
recommends watchful waiting as an option or as favored
good practice: for example in the child over 2 years and
severely ill or still symptomatic after 48 h, in North
America antibiotics are “recommended” whereas in Europe
antibiotics are “optional”. Feedback and/or sanctions on
prescribing practice should be more influential than a
recommendation versus an option. Particular clinical options
tend to be exercised if the alternative is perceived as
therapeutically inactive [18, 46, 62] and naming is an
important part of marketing. The professional term (“watch-
ful waiting” or equivalent) guides physician behavior, but
may not reduce parental concerns: “age-appropriate analge-
sia with active monitoring” would more judiciously reassure
parents.
Are guidelines alone effective in changing practice?
Evidence-based recommendations are necessary, but insuf-
ficient drivers of change. Within an intervention study,
short-term performance improvements (reductions in anti-
biotic prescribing) can be shown, without apparently
compromising parental satisfaction [18, 62, 63]. However,
324 Eur J Pediatr (2011) 170:323–332where physicians know their performance is observed, such
“Hawthorn effects” [38] are expected. This highly con-
trolled evidence shows feasibility and non-harm of rational
prescribing, but does not guarantee long-term adherence to
guidelines.
There remain wide variations in antibiotic prescribing
across Europe [27, 31, 97] and between Europe and the
USA [40], with growing consumption and high resistance
in Asia [90]. The important global question is therefore
whether guidelines will make a large enough difference
soon enough. This urgency requires the analysis of policy
options broader than dissemination of guidelines, partic-
ularly supplementary actions that may help adherence.
Guidelines are alien to much medical tradition, but other
pressures for change in physician role are occurring for
separate reasons, e.g., partnership with, and explanation
to, patients. With a judicious lead and explanation,
parents can change their expectations and behavior,
assisting compliance with guidelines [32, 33]. Effective
implementation of guidelines on any condition can
require physicians to give advice based on the limited
efficacy or unfavorable benefit-to-harm ratio of whole
groups of medicines [66]. In the present phase of
transition to more patient-centered practice, progressive
explanation of more appropriate antibiotic use requires
the complementary use of age-appropriate pain manage-
ment, following a more traditional model of practice. It is
surprising that explicit analgesic alternatives have been
little developed, promoted, or trialed.
Reasons for non-adherence
Non-adherence to guidelines is based on the clinical predic-
ament as experienced by physicians, not on reasoned counter-
claims that guidelines’ aims are somehow inappropriate. The
literature (e.g., Cabana [17]) identifies seven overlapping
classes of reason for poor adherence, many of them cultural,
physician inertia, lack of appropriate incentives, lack of
detailed knowledge due to poor dissemination, conflict of
interest, parental pressure, insufficient use of appropriate
analgesia, uncertain diagnosis, and concerns over possible
complications from not treating infection. Different types of
policy response are required by reasons based on (a)
practical obstacles, (b) clinical counter-arguments that may
be part-justified, and (c) veiled excuses not to practice
effectively or reflectively.
Multi-dimensional cultural differences and the vicious
spiral
Major differences exist between countries in medical
beliefs and practices [74] for economic and cultural
reasons. Compared to Northern and Western Europe,
Southern and Eastern European countries have greater
use of antibiotics [41]. The very low (until recently)
antibiotic prescription rate for AOM in the Netherlands for
OM [34], has been offset by a high rate of early surgical
intervention, often for recurrent AOM rather than OME.
Fig. 1 Trends between 1999
and 2007 in penicillin-resistant
Streptococcus pneumoniae by
country. Reproduced with per-
mission from European Antimi-
crobial Resistance Surveillance
System Annual report 2007
[29]. Available at: http://www.
earss.rivm.nl. Data retrieved
February 2009. Each bar repre-
sents the findings from a single
year. The arrows indicate the
significant trends observed for
all resistant strains (black
arrows) or fully penicillin-
resistant strains (red arrows).
The stars indicate significant
trends in the overall national
data that were, non-significantly,
supported by data from labora-
tories reporting all 9 years. IE
Ireland, IL Israel, IT Italy, BE
Belgium, NL Netherlands, DK
Denmark, FI Finland, FR
France, DE Germany, ES Spain,
SE Sweden, UK United King-
dom
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similar countries shows how cumulative differences in
health beliefs, social determinants, and regulatory practice
produced in France a rate of antibiotic consumption twice
that of Germany [49]. Such accumulations of several
factors [85] resist change if they are mutually reinforcing,
forming vicious spirals (Fig. 2). But a spiral can also
permit large changes, if any of the links become greatly
weakened, e.g., the belief in high efficacy of antibiotics
for AOM.
Parental pressure: the burden of OM on the family
Breaking the spiral requires acknowledgement of the range of
impacts of OM on the family (absence from work with
Table 1 Examples of national guidelines in AOM: scope and recommended first-line treatment






of antibacterials, and preventive
measures
Analgesia




>2 years; watchful waiting
Scottish Intercollegiate Guidelines
Network (SIGN 2003) [88]
Detection, management, referral
and follow-up of AOM and
OM with effusion
Analgesia first-line
Delayed antibiotic treatment after 72 h
National Institute of Clinical Excellence,
UK (NICE 2008) [70]




AOM—no antibiotic or delayed antibiotics
And/or antibiotics for severe cases
Bilateral AOM in children younger than 2 years
AOM in children with otorrhoea
Agence Française de Sécurité Sanitaire
des Produits de Santé
(AFSSAPS 2005) [2]
Best use of antibiotics for
respiratory tract infection
<2 years: antibiotics
>2 years: watchful waiting unless symptoms are
severe then use antibiotics




Antibiotic treatment in OM For purulent OM with effusion or minimally
symptomatic AOM
Amoxicillin prescription to be filled within a week at
the parent’s discretion, if symptoms are worsening
Or deferred treatment following phone call to physician
Guidelines of the German society
for pediatric infectious diseases [36]
Treatment of AOM Symptomatic treatment (analgesia, nose drops) and
watchful waiting for 24–72 h if second look is
assured. Antibiotics first line (amoxicillin) in
severe disease, age<6 months, risk factors
Nederlands Huisarts Genootschap
(NHG) [69]
Treatment of AOM Analgesia (paracetamol)
In case of worsening disease or children
<2 year with bilateral acute OM: amoxicillin for
1 week (recommended alternatives azithromycin
for 3 days or cotrimoxazole for 5–7 days)
Spanish Pediatric Association [23] Treatment of AOM Symptomatic treatment (paracetamol, ibuprofen)
Children >2 years without poor prognostic
factors, analgesic with reassessment after 48 h
Antibiotic is recommended treatment for:
Mild or moderate condition: amoxicillin,
then amoxicillin-clavulanate (if clinical failure at
48–72 h of treatment)
Severe conditions or less than 6 months:
amoxicillin-clavulanate then if clinical failure at
48–72 h of treatment, tympanocentesis and treatment
according to results of Gram staining and
antibiotic sensitivity
Previous treatment failure (lack of clinical response):
amoxicillin-clavulanate then ceftriaxone, then
tympanocentesis and treatment, according
to Gram stain, culture, and sensitivity
326 Eur J Pediatr (2011) 170:323–332possible loss of earnings, extra childcare, loss of family quality
of life, and lowered resilience of the parents to cope with other
problems) [14]. These have not so far been summarized in a
single index, but pressures for consultation and antibiotic use
do reflect these impacts, and so carry implications for the
economic and other choices being modeled. When watchful
waiting was incorporated by Meropol et al. [65]i naf o r m a l
decision analysis, it was suggested that work days lost by
parents of children older than 2 years (compared with <2),
due to prolonged episodes of OM, could pose a genuinely
grounded policy obstacle to rational prescribing.
Physician inertia
Databases on actual clinical activity [3, 81, 83] and surveys
of clinician opinion or professed practice [1, 37, 57, 99]
show poor adherence to guidelines in the real world [82],
making it unlikely that repeating summaries of evidence can
achieve desired changes. One aspect of this inertia is shift in
diagnostic habit, concealing discrepancies between recom-
mended practice and actual prescribing behavior. Some
displacement of former AOM into the separate diagnosis of
OME was noted in the UK [95, 102] recently illustrating the
contradictions of performance management. (Antibiotics are
even less effective in OME, so rarely used, and not subject to
the same guideline strictures.)
Conflicts of interest
In some healthcare systems, a patient/parent can easily
change physician and/or consult more than one practice. In
combination with payment by item of service, these
arrangements make it difficult for physicians to challenge
patient health beliefs [89] and intensify the conflict of
interest between present doctors or parents (to prescribe)
and future patients (to withhold). The conflict becomes
extreme in countries where poorly paid doctors receive a
commission on drugs prescribed.
Fears over the adverse consequences of restricted
prescribing
OM is not zero-risk: some AOM cases progress to
complications such as mastoiditis and intracranial ab-
scess. However, any recent increase in acute mastoiditis
with restraints on prescription is uncertain from the low
event rate and is too small to form a valid objection to
guidelines [94]. The prevention of mastoiditis by routine
antibiotic treatment of AOM has not been directly
established [98]. Thompson and colleagues (2009) showed
in a reference population of 2.6 million that, although
antibiotics roughly halved the risk of mastoiditis, two-
thirds of mastoiditis cases did not have a known
antecedent OM [94]. Thus the estimated number-needed-
to-treat to prevent one episode of mastoiditis, is unaccept-
ably high [94] and routine antibiotic use may even mask
mastoiditis. Physicians and public emphasize the avoid-
ance of serious complications, so progress here requires
not merely revisiting the wording of guidance, but support
for an alternative action: training and dissemination to
encourage prompt referral of suspected mastoiditis to
specialists.
Diagnosis of OM versus severity and persistence
of disease
General practitioners are broadly aware of the distinction
between bacterial and viral infection [16]. In children’s ear
problems, such awareness does not seem to restrain
antibiotic prescription, perhaps because the known viral
facilitation does not rule out bacterial origin or bacterial
development (the prophylactic attitude to mastoiditis being
one extreme). The uncertainties here make the etiological
assumption, (hence antibiotic prescription) culturally arbi-
trary [25]. Until a low-cost non-invasive method to
distinguish bacterial from viral etiology in OM becomes
available, pragmatic guidelines cannot handle this issue
satisfactorily.
Diagnosis of AOM by physicians is currently suboptimal,
with both false-positive and false-negative errors [76]. But
this is only the first step to treatment. Proportionate clinical
response to the severity and persistence/recurrence of OM is
Fig. 2 Vicious seven-stage spiral of antibiotic resistance in a core
transmission group of preschoolers illustrated in the contrast between
France and Germany. The boxes indicate forces which would exist
without the spiral but which help to drive it
Eur J Pediatr (2011) 170:323–332 327required. In epidemiological research this nuancing only
arrived in 1997 for AOM [4] and 1993 for OME [91]. To
cater simply for single-episode diagnosis and treatment,
AOM guidelines have not adequately addressed the grada-
tion issue [48] and the necessary evidence base for it has not
been seriously sought. Proportionate response to severity and
recurrence requires integrating information over time, hence
either high linkage and accessibility of clinical data or long-
term knowledge of the child and family, or both. In the
present transitional era, neither can be assumed.
Possible contributions to a solution
Given these obstacles, various policy elements must be
considered for reducing resistance.
Risk factor reduction
Guidelines from the American Academy of Pediatrics
(AAP) and the American Academy of Family Physicians
(AAFP) have encouraged prevention of OM through
reducing modifiable risk factors. Theoretically, there is
some scope for reducing the size and influence of the core
transmission group [26] via limited use of day care or small
groups; breast feeding beyond 3 months protects against
risk for early OM [5]. However, risk factor intervention in
recurrent AOM meets limited parental willingness to
change behavior [13, 65]. Given (a) the general difficulty
in changing health-related behaviors by education, (b) the
fact that some risk factors are already subject to public
health advice, and (c) the modest relative risk values for
single factors, risk modification is not generally promising.
Training and role evolution for physicians
A large body of research on guideline implementation [8, 12,
37] identifies the most effective forms and channels of
information when updating practice [12, 60]. But healthcare
systems are not mechanistic sets of processes that can be
enduringly optimized: over-use of particular media degrades
their influence with time. For details within conventional
medical paradigms (e.g., which specific antibiotics are
appropriate for first- and second-line management in a
particular setting), physician update education has seemed
effective [77]. To support more radical change adequately,
issues need to be grouped into packages important enough to
command attention and a well-developed educational com-
ponent then rolled out, as in France where one package
improved guideline acceptance [45] and reduced antibiotic
resistance.
De-medicalization (helping patients find alternative non-
medical solutions) has not been a natural role for physicians.
However, the era of the physician as part educator of the
patient and especially as the moderator of other information
sources (such as the internet) began 20 years ago in advanced
countries. Evaluations are beginning to appear of ways within
CME to train this educational role of physicians [54]. Major
recent changes in the management of chronic conditions may
offer principles and precedents for preparing of materials and
procedures that “work”.
Decision support
A new habit may be more readily adopted when supported
by a facility that solves an acknowledged problem; here
information technology offers possibilities. Evidence on
reminders and prompts built into computerized decision
support systems suggests at least short-term reductions in
antimicrobial use and improved appropriateness of antimi-
crobial selection [60], but feedback on performance against
target rates may be more important.
Incentives and related structural changes to manage care
Where healthcare is funded by co-payment systems,
financial incentives to patients can be built in or removed.
Despite some evidence of incentives changing clinical
practice [22], revising payment structures takes resources,
and creates complexities needing to be consolidated or
removed later. Incentives to doctors may have unforeseen
consequences (currently insufficiently researched) such as
the erosion of professional motivation towards appropriate
and cost-effective practice. Alternative responsibility struc-
tures such as pharmacist-led collaborative care, despite
some evidence of effectiveness towards rational prescribing
[60] may not be politically realistic.
Public information campaigns
In Iceland [7]a n dU S A[ 100] correlations have been
shown between physicians’ practices and knowledge or
attitudes about OM. But what is cause and what is effect
here? Various education campaigns (international, national,
regional, and practice-level) including the recent “European
Antibiotic Awareness Day” have improved public knowledge
on antibiotic prescribing, but when used in isolation have not
changed attitudes nor prescribing practice [52, 64, 73, 92].
The evidence for effectiveness of non-targeted campaigns
is at best equivocal [60]. In contrast, assessment of
attitudes informed directly by the physician shows
improved compliance [8].
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Non-typeable Haemophilus influenzae (NTHi) and Strepto-
coccus pneumoniae account for approximately 80% of OM
cases worldwide [44], with NTHi becoming the new
frontier as pneumococcal vaccination spreads [98]. These
two pathogens are responsible for the more severe forms
and sequelae of OM, so effective vaccination against them
could materially reduce OM’s clinical impact and wider
burden [68, 75]. Where antibiotic consumption and other
health costs for childhood OM are high, the cost-saving
argument for vaccination explicitly against OM is already
in place. Where antibiotic consumption is low, the
vaccination scenario is more complex: cost-savings would
need to be accumulated over several disease categories
associated with the two main OM pathogens [44, 59] and
the benefits, including indirect protection, may need to be
measured and accumulated over the severities and preva-
lences of these same categories.
The conjugate heptavalent pneumococcal vaccine, PCV7
(7vCRM, Prevnar™/Prevenar™), was introduced primarily
to prevent invasive pneumococcal disease (IPD: sepsis,
meningitis, pneumonia, and bacteraemia) by universal
vaccination of infants [79], and it appears in some countries
to also benefit adults through herd protection. The large
reduction in IPD was accompanied by a small reduction in
all-cause OM, this via a moderate reduction in pneumococ-
cal OM [10, 11, 51]. To be described as “for” OM, i.e.,
effective against most of the most severe OM, a vaccine
would also require good coverage of pneumococcal sero-
types and of NTHi. An innovative formulation (PhiD-CV,
prototype of the recently licensed Synflorix™) has shown
significant efficacy against AOM from both NTHi and S.
pneumoniae pathogens [21, 80]. Further trials are currently
assessing its effectiveness more fully. PCV7 introduction led
to a shift in the level of acceptable IPD risk in febrile
children, with implications for reduced healthcare use [35].
Further such shifts in risk perception could help dismantle
the vicious spiral, by giving confidence not to prescribe
prophylactically against rare complications [47]. There is
already preliminary evidence in OM that presence of a
vaccination program confers such confidence: 3 years after
introduction of PCV7 in France, antibiotic consumption, as
well as carriage of both resistant and non-resistant strains
were reduced in vaccinated children [20]. Prescribing is the
chief selection pressure in the bacteriological changes post
vaccination, so to further encourage rational prescribing at
introduction of vaccines must slow the need for updating
them [30]. To provide further evidence for policy decisions,
opportunities should be seized for 2×2 studies, powered for
a more-than-additive combination of introducing vaccination
with new (or re-issued) guidelines. This could provide the
desired direct evidence for the probable positive synergy
between vaccination and rational prescribing policies against
antibiotic resistance.
Conclusions
Adherence to guidelines for rational prescribing in AOM
has been poor, so mere existence of guidelines has not
reduced prescription rates sufficiently or enduringly. Policy
initiatives have to directly attack the clinical rationales that
permit continuing physician inertia. Immediately, the
following three steps would help to break the vicious spiral
of antibiotic resistance:
& Strengthening physician education, training, and con-
tinuing professional training towards prevention and
explanation, integrated with clinical decision support
and feedback; also encouraging continuity of care to
manage irrational demand downwards, while providing
assurance and monitoring risk
& Two specific training modules for generalist pediatricians
and family practitioners promoting age-appropriate anal-
gesia and the efficient early identification and manage-
ment of symptomatic mastoiditis
& Vaccination against the most serious pathogens for OM,
shifting the clinical emphasis away from prophylaxis
against serious complications, and from low-effectiveness,
especially in high-prescription countries of older first-line
treatments. The shift in perceived risk following high-
coverage vaccination against OM should help to break the
viciousspiral,butopportunitiesshouldbeseizedtotestthis
conjecture, and to document the a priori partnership
whereby improved adherence to guidelines would de-
crease replacement pressures and so ease the vaccine
development and updating cycle
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